Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Short-term Investments (2016 - 2026)

Scynexis' (SCYX) quarterly Short-term Investments came in at $43.6 million in Q2 2026, up 29.12% on a YoY basis from $33.8 million in Q2 2025, and up 92.97% quarter-over-quarter from $22.6 million in Q1 2026.

Analysis

Scynexis (SCYX) Short-term Investments (2016 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Short-term Investments for 11 consecutive years, with $43.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Short-term Investments rose 29.12% year-over-year to $43.6 million; the trailing twelve-month figure through Jun 2026 stood at $43.6 million (up 29.12% YoY), and the FY2025 full-year result was $18.8 million, down 56.6% from the prior year.
  • Short-term Investments grew to $43.6 million in Q2 2026 per SCYX's latest filing, from $22.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $47.0 million in Q2 2024 and bottomed at $18.8 million in Q4 2025.
  • Historically, Short-term Investments has averaged $34.1 million across 5 years, with a median of $33.7 million in 2025.
  • The sharpest annual moves came in 2024 and 2025: Short-term Investments soared 70.22% in 2024, then plunged 56.6% in 2025.
  • Over 5 years, Short-term Investments stood at $27.7 million in 2022, then soared by 45.59% to $40.3 million in 2023, then grew by 7.29% to $43.2 million in 2024, then slumped by 56.6% to $18.8 million in 2025, then jumped by 132.24% to $43.6 million in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods registered $43.6 million, $22.6 million, and $18.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 43.60 Mn
Mar 31, 2026 22.59 Mn
Dec 31, 2025 18.77 Mn
Sep 30, 2025 23.13 Mn
Jun 30, 2025 33.77 Mn
Mar 31, 2025 33.67 Mn
Dec 31, 2024 43.25 Mn
Sep 30, 2024 40.10 Mn
Jun 30, 2024 47.04 Mn
Mar 31, 2024 44.76 Mn
Dec 31, 2023 40.31 Mn
Sep 30, 2023 44.00 Mn
Jun 30, 2023 27.64 Mn
Mar 31, 2023 27.91 Mn
Dec 31, 2022 27.69 Mn
Sep 30, 2022 27.47 Mn
Jun 30, 2021 55,000.00
Mar 31, 2021 55,000.00
Sep 30, 2020 55,000.00
Jun 30, 2020 3.60 Mn